{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105053","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.145958+00:00","generated_at":"2026-05-17T17:28:14.768455+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CytomX Q2 2025 cash $158.1M; positive CX-2051 Phase 1 data; $100M offering closed","bullets":["Revenue $18.7M in Q2 2025 vs $25.1M in Q2 2024; operating expenses fell to $19.9M from $33.6M.","Cash, equivalents and investments $158.1M at June 30, 2025, up from $79.9M on March 31, 2025; cash runway to Q2 2027.","Positive interim data from CX-2051 Phase 1 in advanced colorectal cancer; dose expansions initiated at 7.2, 8.6, 10 mg/kg Q3W.","CX-2051 Phase 1 data update on ~70 patients by Q1 2026; Phase 2 study in late-line CRC expected in 1H 2026.","Completed $100M underwritten offering, net proceeds $93.4M; CX-801 plus KEYTRUDA dose escalation started for advanced melanoma."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105053","json":"https://secwatch.observer/filing/0000950170-25-105053.json","markdown":"https://secwatch.observer/filing/0000950170-25-105053.md","text":"https://secwatch.observer/filing/0000950170-25-105053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017025105053/0000950170-25-105053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017025105053/ctmx-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:28:14.768455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}